Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

35.97USD
23 May 2018
Change (% chg)

$0.25 (+0.70%)
Prev Close
$35.72
Open
$35.68
Day's High
$36.03
Day's Low
$35.63
Volume
18,760,189
Avg. Vol
24,143,354
52-wk High
$39.43
52-wk Low
$31.67

Latest Key Developments (Source: Significant Developments)

ACCC Unsuccessful In Appeal Against Pfizer
Thursday, 24 May 2018 11:56pm EDT 

May 25 (Reuters) - Australian Competition and Consumer Commission::FULL COURT OF THE FEDERAL COURT OF AUSTRALIA DISMISSED APPEAL BY ACCC AGAINST EARLIER JUDGMENT IN RELATION TO PFIZER AUSTRALIA PTY LTD.  Full Article

FDA Grants Breakthrough Therapy Designation For Pfizer's Tafamidis
Wednesday, 23 May 2018 08:00am EDT 

May 23 (Reuters) - Pfizer Inc ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR TAFAMIDIS FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY.PFIZER INC - DECISION IS SUPPORTED BY TOPLINE RESULTS FROM TAFAMIDIS PHASE 3 TRANSTHYRETIN CARDIOMYOPATHY (ATTR-ACT) STUDY.  Full Article

Trial shows Pfizer's Lyrica reduces seizures in children with epilepsy
Thursday, 17 May 2018 08:00am EDT 

May 17 (Reuters) - Pfizer Inc ::LYRICA® (PREGABALIN) ORAL SOLUTION CV PHASE 3 TRIAL IN PEDIATRIC EPILEPSY MEETS PRIMARY ENDPOINT.PFIZER - POSITIVE TOP-LINE RESULTS OF PHASE 3 STUDY EXAMINING USE OF LYRICA ORAL SOLUTION CV AS ADJUNCTIVE THERAPY.PFIZER - RESULTS SHOWED ADJUNCTIVE TREATMENT WITH LYRICA 14 MG/KG/DAY RESULTED IN STATISTICALLY SIGNIFICANT REDUCTION IN SEIZURE FREQUENCY VERSUS PLACEBO.PFIZER INC - TREATMENT WITH LYRICA AT LOWER DOSE DID NOT RESULT IN STATISTICALLY SIGNIFICANT REDUCTION IN SEIZURE FREQUENCY VERSUS PLACEBO.  Full Article

Pfizer’S Biosimilar Retacrit® (Epoetin Alfa-Epbx) Approved By U.S. FDA
Tuesday, 15 May 2018 02:38pm EDT 

May 15 (Reuters) - Pfizer Inc ::PFIZER’S BIOSIMILAR RETACRIT® (EPOETIN ALFA-EPBX) APPROVED BY U.S. FDA.PFIZER INC - RETACRIT IS EXPECTED TO BE AVAILABLE IN U.S. AT A SIGNIFICANT DISCOUNT TO CURRENT WHOLESALER ACQUISITION COST OF EPOGEN AND PROCRIT.PFIZER INC - ENTERED AGREEMENT WITH VIFOR PHARMA INC FOR COMMERCIALIZATION OF RETACRIT IN CERTAIN CHANNELS.  Full Article

U.S. FDA Approves Retacrit As Biosimilar To Epogen/Procrit For Treatment Of Anemia
Tuesday, 15 May 2018 11:32am EDT 

May 15 (Reuters) - The U.S. Food and Drug Administration::SAYS APPROVED RETACRIT AS BIOSIMILAR TO EPOGEN/PROCRIT FOR TREATMENT OF ANEMIA.SAYS GRANTED APPROVAL OF RETACRIT TO HOSPIRA INC, A PFIZER COMPANY.SAYS AS WITH EPOGEN/PROCRIT, RETACRIT CONTAINS BOXED WARNING ABOUT INCREASED RISKS OF DEATH, HEART PROBLEMS, STROKE, TUMOR GROWTH OR RECURRENCE.SAYS APPROVAL OF RETACRIT FOR TREATMENT OF ANEMIA CAUSED BY CHRONIC KIDNEY DISEASE, CHEMOTHERAPY, OR USE OF ZIDOVUDINE IN PATIENTS WITH HIV INFECTION.SAYS RETACRIT HAS BEEN APPROVED AS A BIOSIMILAR, NOT AS AN INTERCHANGEABLE PRODUCT.  Full Article

Xtalpi Says Research Collaboration With Pfizer To Develop Artificial Intelligence-Powered Software Platform
Tuesday, 8 May 2018 10:30am EDT 

May 8 (Reuters) - Xtalpi Inc::XTALPI INC - STRATEGIC RESEARCH COLLABORATION WITH PFIZER TO DEVELOP A HYBRID PHYSICS- AND ARTIFICIAL INTELLIGENCE-POWERED SOFTWARE PLATFORM.  Full Article

Pfizer Doses First Patient Using Investigational Mini Dystrophin Gene Therapy For The Treatment Of Duchenne Muscular Dystrophy
Thursday, 12 Apr 2018 08:00am EDT 

April 12 (Reuters) - Pfizer Inc ::PFIZER DOSES FIRST PATIENT USING INVESTIGATIONAL MINI-DYSTROPHIN GENE THERAPY FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.EARLY DATA FROM MINI-DYSTROPHIN GENE THERAPY STUDY TRIAL ARE EXPECTED IN FIRST HALF OF 2019 .  Full Article

Pfizer Doses First Patient Using Investigational Mini Dystrophin Gene Therapy For The Treatment Of Duchenne Muscular Dystrophy
Thursday, 12 Apr 2018 08:00am EDT 

April 12 (Reuters) - Pfizer Inc ::DYSTROPHIN GENE THERAPY FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.DYSTROPHIN GENE THERAPY STUDY TRIAL ARE EXPECTED IN FIRST HALF OF 2019.  Full Article

Pfizer Announces Tafamidis Phase 3 ATTR-ACT Study Met Its Primary Endpoint
Thursday, 29 Mar 2018 12:45pm EDT 

March 29 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ATTR-ACT STUDY OF TAFAMIDIS IN PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY.PFIZER INC - STUDY MET ITS PRIMARY ENDPOINT.PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED.PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED IN POPULATION AND NO NEW SAFETY SIGNALS WERE IDENTIFIED.  Full Article

Reckitt Benckiser Ends Discussions For Parts Of Pfizer's Consumer Health business
Wednesday, 21 Mar 2018 04:05pm EDT 

March 21 (Reuters) - Reckitt Benckiser Group Plc ::RECKITT BENCKISER SAYS PULLS OUT OF PFIZER CONSUMER HEALTH AUCTION.CO'S PROPOSAL WAS FOR PART OF THE BUSINESS ONLY.RECKITT BENCKISER - ACQUISITION FOR WHOLE PFIZER CONSUMER HEALTH BUSINESS DID NOT FIT ACQUISITION CRITERIA, ACQUISITION OF PART OF BUSINESS WAS NOT POSSIBLE.  Full Article

Photo

Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales

MELBOURNE An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor.